GVI Holdings

GVI Holdings, primarily operating through its subsidiary GVI Biopharma (formerly the non-profit Global Vaccines, Inc.), was a clinical-stage biotechnology company focused on the development of vaccines for infectious diseases. The company utilized a proprietary alphavirus replicon technology platform to create highly potent vaccine candidates designed to elicit robust immune responses. Its lead program, GVI-HIV-01, was a novel HIV vaccine candidate that reached Phase 1 clinical testing. Beyond HIV, the company maintained early-stage research programs targeting other global health priorities, including malaria and dengue fever. Based in the Research Triangle Park region, GVI aimed to bridge the gap between academic discovery and commercial vaccine production for underserved populations.